CJC-1295 (with DAC)

Evidence Limitation: The safety profile for CJC-1295 with DAC is based on extremely limited clinical evidence. Only one recent review article was identified, and no formal clinical trials were retrieved from established databases.

Known Side Effects

Due to the lack of controlled clinical trials, the complete side effect profile of CJC-1295 with DAC remains poorly characterized. The available evidence does not provide reliable data on the frequency, severity, or duration of potential adverse effects.

Based on its mechanism as a growth hormone-releasing hormone analog, potential side effects may theoretically include those associated with elevated growth hormone levels, but specific documented reactions for CJC-1295 with DAC are not well-established in the medical literature.

Contraindications

Evidence Gap: No formal contraindications have been established through clinical trials. Without proper safety studies, contraindications cannot be reliably determined.

Drug Interactions

No Documented Interactions: The available evidence does not provide information about potential drug interactions with CJC-1295 with DAC. This represents a significant knowledge gap rather than evidence of safety.

Populations That Should Avoid Use

Evidence Insufficient: Due to the lack of clinical trial data, specific populations that should avoid CJC-1295 with DAC cannot be definitively identified based on established evidence. Standard precautionary principles would suggest avoiding use in:

• Pregnant or nursing women
• Children and adolescents
• Individuals with active malignancies
• Those with uncontrolled medical conditions

However, these recommendations are based on general safety principles rather than specific evidence for this compound.

Important Safety Considerations

The 2026 review highlights a concerning gap between patient self-administration and clinical evidence for performance-enhancing peptides affecting the GH-IGF1 axis, including CJC-1295 with DAC. This suggests widespread use without adequate safety data.

Disclaimer: This information is for educational purposes only and should not replace professional medical advice. The limited evidence available makes it impossible to provide comprehensive safety guidance. Individuals considering this compound should consult with healthcare providers familiar with peptide therapies.